Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,296.19
(
-0.07%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 228495

Thursday, 04/30/2020 4:33:23 PM

Thursday, April 30, 2020 4:33:23 PM

Post# of 257300
GILD 1Q20 HCV sales=$729M, +16% QoQ, -8% YoY. The geographic breakdown was: US $398M; EU $148M; RoW $183M.

http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-first-quarter-2020-financial-results

GILD’s worldwide HCV patient starts in 1Q20 (CC slide #43) was flat vs 4Q19 at 45K (increasing from 28K to 29K in the US), implying an increase in average selling price per HCV patient.

--
CC slides:
http://investors.gilead.com/static-files/af4599eb-4fb8-4cf7-96a1-38caf477e9b4

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now